Skip to content
DataLookout
Menu

NCT07175233

A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 5 more changesShow less
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary completion date changed from estimate of Aug 15, 2026 to Sep 23, 2026
    • Study completion pushed from Aug 20, 2027 to Nov 30, 2027
    • Start date changed from estimate of Oct 27, 2025 to Oct 28, 2025
    • Site details revised at 2 of 2 sites
  2. Minor Study title shortened, about 2 wordsv3
  3. Minor Study title shortened, about 3 wordsv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 16 (W16).
Timeframe: At Week 16 (W16)

Arms and interventions

cohort 1- Low dose groupExperimental
cohort 2-Medium dose groupExperimental
cohort 3-High dose groupExperimental
cohort 4- placebo groupPlacebo comparator

Drugs: SIM0278 injection

Other: Placebo

Sites

2 sites in 1 country